Aiming to simultaneously modulate the endocannabinoid system (ECS) functions and the epigenetic machinery, we selected the fatty acid amide hydrolase (FAAH) and histone deacetylase (HDAC) enzymes as desired targets to develop potential neuroprotective multitarget-directed ligands (MTDLs), expecting to achieve an additive or synergistic therapeutic effect in oxidative stress-related conditions. We herein report the design, synthesis, and biological evaluation of the first-in-class FAAH-HDAC multitarget inhibitors. A pharmacophore merging strategy was applied, yielding 1-phenylpyrrole-based compounds 4a-j. The best-performing compounds (4c, 4f, and 4h) were tested for their neuroprotective properties in oxidative stress models, employing 1321N1 human astrocytoma cells and SHSY5 human neuronal cells. In our preliminary studies, compound 4h stood out, showing a balanced nanomolar inhibitory activity against the selected targets and outperforming the standard antioxidant N-acetylcysteine in vitro. Together with 4f, 4h was also able to protect 1321N1 cells from tert-butyl hydroperoxide or glutamate insult. Our study may provide the basis for the development of novel MTDLs targeting the ECS and epigenetic enzymes.Aiming to concurrently modulate the endocannabinoid system and the epigenetic machinery, the first-in-class fatty acid amide hydrolase-histone deacetylase multitarget inhibitors 4a-j were developed as potential neuroprotective agents. 4h showed balanced inhibitory activity against the selected targets, without cytotoxicity. 4h, f reduced the production of reactive oxygen species in tert-butyl hydroperoxide-stressed 1321N1 cells and protected against glutamate-induced damage.image

Papa, A., Cursaro, I., Pozzetti, L., Contri, C., Cappello, M., Pasquini, S., et al. (2023). Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents. ARCHIV DER PHARMAZIE, 356(12), 1-22 [10.1002/ardp.202300410].

Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents

Cursaro, Ilaria;Carullo, Gabriele;Gemma, Sandra;Butini, Stefania
;
Campiani, Giuseppe;
2023-01-01

Abstract

Aiming to simultaneously modulate the endocannabinoid system (ECS) functions and the epigenetic machinery, we selected the fatty acid amide hydrolase (FAAH) and histone deacetylase (HDAC) enzymes as desired targets to develop potential neuroprotective multitarget-directed ligands (MTDLs), expecting to achieve an additive or synergistic therapeutic effect in oxidative stress-related conditions. We herein report the design, synthesis, and biological evaluation of the first-in-class FAAH-HDAC multitarget inhibitors. A pharmacophore merging strategy was applied, yielding 1-phenylpyrrole-based compounds 4a-j. The best-performing compounds (4c, 4f, and 4h) were tested for their neuroprotective properties in oxidative stress models, employing 1321N1 human astrocytoma cells and SHSY5 human neuronal cells. In our preliminary studies, compound 4h stood out, showing a balanced nanomolar inhibitory activity against the selected targets and outperforming the standard antioxidant N-acetylcysteine in vitro. Together with 4f, 4h was also able to protect 1321N1 cells from tert-butyl hydroperoxide or glutamate insult. Our study may provide the basis for the development of novel MTDLs targeting the ECS and epigenetic enzymes.Aiming to concurrently modulate the endocannabinoid system and the epigenetic machinery, the first-in-class fatty acid amide hydrolase-histone deacetylase multitarget inhibitors 4a-j were developed as potential neuroprotective agents. 4h showed balanced inhibitory activity against the selected targets, without cytotoxicity. 4h, f reduced the production of reactive oxygen species in tert-butyl hydroperoxide-stressed 1321N1 cells and protected against glutamate-induced damage.image
2023
Papa, A., Cursaro, I., Pozzetti, L., Contri, C., Cappello, M., Pasquini, S., et al. (2023). Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents. ARCHIV DER PHARMAZIE, 356(12), 1-22 [10.1002/ardp.202300410].
File in questo prodotto:
File Dimensione Formato  
2023_Archiv der Pharmazie -FAAH‐HDAC_final.pdf

accesso aperto

Licenza: Creative commons
Dimensione 5.75 MB
Formato Adobe PDF
5.75 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1252915